{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:53:31Z","timestamp":1778756011420,"version":"3.51.4"},"reference-count":23,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ocul Oncol Pathol"],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Uveal melanoma (UM) is the most common intraocular tumour in adults. Currently there are different tests available to determine the risk of UM for metastasis, among which include BRCA1-associated protein-1 (BAP1) immunohistochemistry (IHC) and gene expression profiling (GEP). BAP1 is a deubiquitylating enzyme (DUB) that has tumour suppressor activity, the loss of which therefore is associated with higher risk for tumour growth and metastasis. &lt;b&gt;&lt;i&gt;Objectives:&lt;\/i&gt;&lt;\/b&gt; To compare and correlate the prognostic significance of BAP1-IHC staining patterns and GEP in the prediction of UM\u2019s risk for metastasis. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; This is a retrospective chart review with prospective follow-up of patients with primary UM who underwent enucleation from the year 2008 to 2018. Clinical history, histopathologic findings, GEP classification, BAP1-IHC of the formalin-fixed paraffin-embedded tissues, and follow-up data for metastasis were collected and statistically analysed. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; A total of 30 enucleated eyes with UM were included in the study. All class 1a tumours had high nuclear BAP1 expression and all class 2 had low nuclear BAP1 expression. Fifty percent of the class 1b tumours had low nuclear BAP1 expression. Among the tumours with low nuclear BAP1 expression, 68% developed metastasis, while 9% developed metastasis among high nuclear expression. Fifty-five percent developed metastasis in tumours with high cytoplasmic expression and 42% for low cytoplasmic expression. Predictive values for metastasis (positive predictive value, negative predictive value) are as follows: (1) nuclear BAP1-IHC (68%, 91%), (2) cytoplasmic BAP1-IHC (55%, 58%), and (3) GEP (73%, 80%). Nuclear BAP1-IHC and GEP had the same accuracy rate of 77% and cytoplasmic BAP1-IHC had an accuracy of 57%. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; Low nuclear BAP1-IHC strongly correlates with GEP class 2 and was equally accurate in the prediction of metastasis.<\/jats:p>","DOI":"10.1159\/000502550","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T21:00:32Z","timestamp":1568926832000},"page":"129-137","source":"Crossref","is-referenced-by-count":33,"title":["BAP1 Immunoreactivity Correlates with Gene Expression Class in Uveal Melanoma"],"prefix":"10.1159","volume":"6","author":[{"given":"Thonnie\u00a0Rose","family":"See","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-8911","authenticated-orcid":false,"given":"Gustav","family":"St\u00e5lhammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans\u00a0E.","family":"Grossniklaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2019,9,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2630"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000480640"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0538"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-017-0650-3"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2010.090220"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.06.012"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.0903"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.11.019"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2401"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-371"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1126\/science.1194472"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000645"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.417"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000002"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.03.005"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.07.018"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22541"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201861"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(84)90457-4"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1309085110"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3355"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.03.002"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305047"}],"container-title":["Ocular Oncology and Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/502550","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/502550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:52:48Z","timestamp":1745423568000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000502550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,19]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,3,3]]},"published-print":{"date-parts":[[2020,3,11]]}},"URL":"https:\/\/doi.org\/10.1159\/000502550","archive":["Portico"],"relation":{},"ISSN":["2296-4681","2296-4657"],"issn-type":[{"value":"2296-4681","type":"print"},{"value":"2296-4657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,19]]}}}